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Increased Th17-Related Cytokine Serum Levels in
Patients With Multiple Polyps of Unexplained Origin
Miren Alustiza, MS1, Eva Herna´ndez-Illa´n, PhD1, Miriam Jua´rez, PhD1, Mar Giner-Calabuig, MS1, Cristina Mira, MS2,
Alejandro Martínez-Roca, MS1, Luis Bujanda, MD, PhD3, Francisco Rodríguez-Moranta, MD, PhD4, Joaquín Cubiella, MD, PhD5,
Luisa de-Castro, MD, PhD6, Jose´-Carlos Marín-Gabriel, MD, PhD7, Alberto Herreros-de-Tejada, MD, PhD8,
Fernando Ferna´ndez-Bañares, MD, PhD9, David Nicola´s-Pe´rez, MD, PhD10, Paula Gime´nez, PhD11, Claudia Martínez-Cardona, PhD11,
Rube´n France´s, PhD11,12, Oscar Murcia, MD, PhD1,2 and Rodrigo Jover, MD, PhD1,2
OBJECTIVES: Most patientswithmultiple colonic polyps do not have a known genetic or hereditary origin. Our aimwas
to analyze the presence of inflammatory cytokines and levels of glucose, insulin, and C-reactive protein
(CRP) in patients with multiple colonic polyps.
METHODS: Eighty-three patients with 10 ormore adenomatous or serrated polyps and 53 control people with normal
colonoscopy were included. Smoking habits were registered, and glucose, CRP, and basal insulin in the
serum/blood weremeasured. Quantification of IL-2, IL-4, IL-6, IL-10, IL-11, IL-17A, and IL-23 cytokine
levels in the serum was performed by a high-sensitivity enzyme-linked immunosorbent assay.
RESULTS: Smoking and diabetesweremore prevalent in thosewith colonic polyps than in the control people (67% vs
16%, P5 0.001; 11% vs 2%, P5 0.048). In addition, the cytokine serum levels were higher, i.e., IL-2
(P5 0.001), IL-4 (P5 0.001), IL-6 (P5 0.001), IL-17A (P5 0.001), IL-23 (P5 0.014), and CRP
(P5 0.003). Adjusting for sex, smoking, and diabetes in a multivariate analysis, IL-2, IL-4, IL-6, IL-17A,
and IL-23 remained independently elevated in cases with multiple polyps.
DISCUSSION: These results indicate that immune responses mediated by Th17 cells may be involved in the
pathogenesis of multiple colonic polyps.
Clinical and Translational Gastroenterology 2020;11:e00143. https://doi.org/10.14309/ctg.0000000000000143
INTRODUCTION
Aphenotypeofmultiple colonicpolyps is a frequentfinding in fecal
immunochemical test–based colorectal cancer (CRC) screening
programs. Some of these cases are due to germline mutations in
either APC or MUTYH genes; such mutations are found in no
more than 20%–30% of all cases (1–4). However, in most cases of
attenuated polyposis, no genetic cause for this phenotype is found,
and these multiple colonic polyps are of unknown origin. In these
cases, an attenuated polyposis could be due to the involvement of
other unknown high predisposition genes or potentially related to
environmental factors (5).
The potential risk factors for this multiple colonic polyp phe-
notype may include those that have been previously described as
risk factors for the development of sporadic adenomas or serrated
polyps, such as obesity, smoking, metabolic syndrome, or other
factors related to increased inflammatory response. One of the
most relevant immunological pathways sustaining chronic in-
flammation consist of the differentiation and expansion of the
adaptive T helper (Th)17 response. An increase of Th17 cell sub-
lineage and IL-17/IL-23 levels has been linked to obesity (6,7) and
smoking (8). This proinflammatory route is triggered and stabi-
lized after microenvironment upregulation of interleukin (IL)-6
and IL-23 concentrations, respectively. Although IL-23 and
the Th17 main cytokine product IL-17 have been described
to importantly contribute to colorectal tumorigenesis and
inflammation-related cancer (9), these cytokine levels have not
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been evaluated so far in the serum of patients withmultiple colonic
polyps. Because these proinflammatory cytokines activate and
perpetuate intracellular signaling through STAT3 and nuclear
factor kB (10), which are the 2 major factors linking inflammation
to cancer, their serum concentration increment would suggest an
explanation for tumor development through a polarized Th17
sustained response in these patients. In fact, patients with an at-
tenuated polyposis are at increased risk of developing CRC com-
paredwith the general population (11). The aimof this studywas to
analyze the association between serum inflammatory cytokines
and the presence of the phenotype of multiple colonic polyps of
unknown origin.
MATERIALS AND METHODS
Study population
An attenuated polyposis was defined as the presence of 10–99
synchronous adenomatous or serrated polyps at endoscopy.
Patients came from the EPIPOLIP registry, a nationwide multi-
center registry that investigated the causes of multiple colonic pol-
yps and incorporated patients from 24 Spanish hospitals (12).
Patients diagnosed with inflammatory bowel disease or those with
hyperplastic rectosigmoid polyps as the only finding were not in-
cluded in the registry. For this particular substudy, patients were
prospectively recruited when fulfilling the inclusion criteria, and
a blood sample was obtained at the time of inclusion, after colo-
noscopy and polypectomy. Patients with APC or MutYH germline
pathogenic variants were excluded, and inclusion of patients with
variants of uncertain significance in APC and MUTYH was
allowed. Healthy controls were recruited at the Endoscopy Unit of
the Hospital General Universitario de Alicante from subjects un-
dergoing a colonoscopy because of symptoms or a positive fecal
immunochemical test with a normal result in this colonoscopy. The
exclusion criteria for both cases and controls were a history of CRC,
inheritedCRCsyndromes, such as theLynch syndromeand familial
adenomatous polyposis, previous intestinal resection, and concur-
rent chronic bowel disorders, such as inflammatory bowel disease.
Clinical and environmental risk factors
Information about age, sex, number, location, size and histolog-
ical type of polyps, body mass index, smoking habit (active and
former smokers), and diagnosis of diabetes mellitus (DM) was
obtained at recruitment. In addition, at inclusion, fasting serum
levels of glucose and insulin were collected in cases and controls.
Glucose was measured by an enzymatic method by using hexo-
kinase (Roche/Hitachi, Mannheim, Germany), Cobas 8000. A
homeostatic model assessment of insulin resistance (HOMA-IR)
was calculated using the formula (Glucose 3 Insulin)/405.
Polyps
Adenomatous polyps included tubular, tubulovillous, and villous
adenomas. Serrated polyps included hyperplastic polyps, sessile
serrated polyps, and traditional serrated adenomas (13). Serrated
polyposis syndrome (SPS) was diagnosed when theWHO criteria
for this disease were fulfilled (13). Patients with an attenuated
polyposis were classified into 2 groups: adenomatous and ser-
rated. Adenomatous polyposis was consideredwhen.50%of the
polyps were adenomatous. Serrated polyposis was considered
when.50%of the polypswere serrated. SPSwas considered if the
patients met the WHO criteria for this disease (13).
Serum inflammatory markers
Blood sampleswereobtained in cases and controls formeasurement
of serum inflammatory markers. Serum levels of the human in-
flammatory markers IL-2 and TNF-a (as markers of early in-
flammation and lymphocyte activation, respectively), interferon
gamma (IFN-g) (as a Th1 marker), IL-4 (as a marker), IL-6, IL-23,
and IL-17 (asTh17markers), and regulatory IL-10weredetermined
by the commercially available high-sensitivity enzyme-linked im-
munosorbent assay (ELISA) kits using standard protocols. The
levels of IL-2, IL-4, IL-6, IL-10, IL-11, IL-23, and IFN-g were de-
termined by the high-sensitivity ELISA kits, following the manu-
facturer’s protocol (Abcam, Cambridge, United Kingdom). Serum
IL-17Awas detected using a high-sensitivity ELISA (#BMS2017HS,
eBioscience, Vienna, Austria) and TNF-a (BMS223HS, Bender
MedSystems GmbH, Vienna, Austria). Serum C-reactive protein
(CRP) levelsweremeasured using an in vitro immunoturbidimetric
method (Roche/Hitachi), Cobas 800.
Statistical analyses
Data analyses were performed with SPSS software (SPSS 19.0,
Chicago, IL). Continuous variables were reported as themean, SD,
and interquartile range (P25–P75). Normal distribution of con-
tinuous variables was evaluated using the Kolmogorov–Smirnov
test. Frequencies or percentages were used to report categorical
variables. Differences between samples were determined with the
Mann–WhitneyU test for nonparametric quantitative data and the
Student t test for parametric data. The x2 method for categorical
data followed by the Yates correction or Fisher exact test was used
to analyze statistical differences between the groups. We included
univariate and multivariate linear regression models to determine
the association between factors, such as smoking, DM, and be-
longing to the case or control group. Both analyses were performed
after adjusting for the sex of patients. In addition, variables found to
be significant in the univariate analysis were included in the mul-
tivariate analysis. Both univariate and multivariate models were
considered statistically significant at P, 0.05.
RESULTS
Descriptive characteristics of the multiple colonic polyps of
unknown origin phenotype in patients and controls
The study group included 83 patients with an endoscopic di-
agnosis of attenuated polyposis and 52 controls with normal
colonoscopy. The descriptive data of case-control individuals
are summarized in Table 1. We included 71 men (86%) and 12
women (14%) in the case group and 42 men (81%) and 10
women (19%) in the control group (P 5 0.481). A total of 55
cases (66%) were smokers compared with 14 (27%) controls
(P 5 0.001). Moreover, 9 cases (11%) had DM, and only 1
control (2%) showed this condition (P5 0.048). There were no
differences in mean HOMA-IR and mean body mass index
between cases and controls (4.3 6 5.2 vs 3.2 6 1.8, P 5 0.083;
and 27.6 6 4.8 vs 28.7 6 3.7, P 5 0.255, respectively).
Inflammatory markers
In the univariate analysis, several inflammatory markers were as-
sociated with the presence of multiple colonic polyps. Serum
concentrations of IL-2 (2.5 vs 0.2 pg/mL; P 5 0.001), IL-4 (4.2 vs
0.07 pg/mL; P5 0.001), IL-6 (3.5 vs 0.5 pg/mL;P5 0.001), IL-17A
(1.5 vs 0.3 pg/mL; P5 0.001), IL-23 (6.4 vs 2.0 pg/mL; P5 0.014),
and CRP (4.5 mg/L vs 0.2 mg/L; P 5 0.001) were significantly
increased in patients with polyposis compared with controls. None
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of the other factors (IL-10, IL-11, TNF-a, and IFN-g) were related
to the development of colon polyps in this study (Table 2).
In the multivariate analysis, after adjusting for sex, smoking,
and history of DM, only having attenuated polyposis was in-
dependently associated with an increase in inflammatory markers
(Table 3). All the factors that were significantly associated with
polyp development in the univariate analysis were identified as
independent predictors in the linear regression analysis: IL-2 (P,
0.001), IL-4 (P, 0.001), IL-17A (P, 0.001), IL-6 (P, 0.001), IL-
23 (P 5 0.001), and CRP (P 5 0.003). The relationship between
multiple colonic polyps and the Th17 pathway can be seen in
Figure 1.
No correlation was found for IL-17Awith IL-2 or for IL-4 and
IL-23 with IL-2 and IL-4. By contrast, IL-17A and IL-23 did show
a correlation (r5 0.419; P , 0.001).
Classification and characteristics of the polyps and their
relationship with inflammatory markers
Adenomatous polyposis was diagnosed in 46 cases (55%) and
serrated polyposis in 37 cases (45%). Eight patients met the cri-
teria for SPS. We found a mean of 23 (SD 13) polyps per person,
and the mean of both serrated and adenomatous polyps per
person was 9 (SD 12). A total of 25 patients (30%) showed more
than 10 adenomas. Characteristics of polyps can be seen in
Table 4. Concentrations of the investigated cytokines were not
different between adenomatous and serrated polyposis except for
TNF-a, the concentration of which was 5-fold higher in the
serrated group (0.5 vs 2.7, P 5 0.010) (Table 5).
DISCUSSION
Themain result of our study is that, when adjusted by smoking and
presence of DM, several soluble inflammatory markers associated
with different immune activities are independently related to the
existence of an attenuated polyposis of unknown origin. Specifi-
cally, a Th17-related cytokine response is significantly increased in
patients with multiple colonic polyps. As these patients remain
“genetic orphans” because no constitutional mutation can be
demonstrated (14), our findings may be hypothesis generating for
future studies aimedat linking sustained inflammatorypathways to
the development of multiple colonic polyps and open the possi-
bility of investigating the potential immunomodulatory treatments
for this condition. This phenotype is uncommon in primary
screening colonoscopy but increasingly found in FIT-based CRC
screening individuals.
The relationship between inflammation and neoplasia has
long been supported, and epidemiological, pharmacological,
and genetic evidence provide solid support that inflammation
can increase cancer risk and promote tumor progression (15).
Thus, studies have shown that individuals with chronic in-
flammatory bowel disease have a higher risk of CRC than those
without such a condition (16,17). Animal models with contin-
uous inflammatory conditions are predisposed to CRC de-
velopment (18). In the case of colitis-associated cancer, it was
suggested that chronic inflammation and colonic injury might
directly cause DNA alterations (19,20). Now, it is generally ac-
cepted that up to 25% of human malignancies are related to
chronic inflammation, including viral and bacterial infec-
tions (21).
There are studies supporting the relationship of CRP with CRC
(22–24), and a positive association between CRP and the preva-
lence of large adenomas has been reported. Although CRP
constitutes a solid soluble marker of inflammation, CRP is an
acute-phase inflammatory marker and its utility in identifying
inflammatory pathways is very limited. On the contrary, different
cytokines associated with specific inflammatory responses may be
of help in this regard. Several studies have shown that colonic
adenomas exhibit upregulation of IL-23 and IL-17 expression
relative to adjacent nontumor tissue (25,26). Furthermore, serum
IL-17A levels are elevated in patients with CRC compared with
healthy individuals (27), and increased IL-6 has been involved in
the development of sporadic CRC and colitis-associated cancer
(28) and associated with increased CRC risk (29).
In the present study, although CRP is also elevated, Th17-
associated IL-6, IL-23, and IL-17 cytokine levels are in-
dependently related to the existence of an attenuated polyposis
of unknown origin. These results point to the differentiation and
proliferation of an adaptive Th17 cell response in this pheno-
type. In fact, IL-2 increased levels, evaluated as a marker of
Table 1. Descriptive characteristics of patients with multiple
colonic polyps and controls
Cases (n 5 83) Controls (n 5 52) P
Age, mean 6 SD (yr) 59.986 13.6 61.246 6.67 0.443
Sex, % (n)
Men 85.5% (71) 81% (42) 0.481
Women 14.5% (12) 19% (10)
Smokers, % (n) 66% (55) 26.5% (14) 0.001a
Diabetes mellitus, % (n) 11% (9) 2% (1) 0.048a
HOMA-IR, mean 6 SD 4.36 5.2 3.26 1.8 0.083
BMI, mean 6 SD (kg/m2) 27.6 6 4.8 28.7 6 3.7 0.255
BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin
resistance.
aResults are statistically significant.
Table 2. Cytokines and inflammatory marker values in cases and
controls
Cases (n5 83) Controls (n 5 52) P
IL-17A 1.56 1.4 (0–2) 0.36 0.9 (0–0) ,0.001a
IL-23 6.4 6 4.9 (2.4–9.4) 2.0 6 5.9 (0–2.6) ,0.001a
IL-11 8.3 6 15.0 (0–7.7) 12.6 6 24.4 (0–17.4) 0.441
IL-10 4.36 5.9 (0–7) 4.36 7.7 (1.5–3.0) 0.409
IL-2 2.56 3.9 (0–4.1) 0.2 6 0.9 (0–0) ,0.001a
IL-4 4.26 6.4 (0–7.8) 0.07 6 0.3 (0–0) ,0.001a
IL-6 3.56 5.1 (0–5.4) 0.5 6 1.0 (0–0) ,0.001a
CRP 4.56 8.3 (0–8.4) 0.2 6 0.2 (0–0) ,0.001a
TNF-a 0.96 3.3 (0–0) 1 6 4.6 (0–0) 0.509
IFN-g 1.36 3.6 (0–0) 1.36 5.6 (0.0) 0.792
All cytokine and inflammatory marker levels are presented as mean 6 SD.
Interquartile ranges are expressed between parentheses.
aResults are statistically significant using the Mann–Whitney U test.
CRP, C-reactive protein; IFN, interferon; IL, interleukin; TNF, tumor necrosis
factor.
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T-cell activation, would support this assumption. However, and
despite the solid data on 3 different cytokines of the Th17
pathway, the study design does not allow us to prospectively
evaluate patients’ antigen-presenting cells in coculture with
naive T cells for functional characterization and immunophe-
notyping. This limitation, along with the increment in serum
levels of IL-4, an indirect marker of a Th2 profile, prevents us
from discarding the differentiation of other inflammatory
pathways and their coexistence with the Th17 cascade. Sup-
porting this, IL-4 is overexpressed in early events of CRC de-
velopment, including hyperplastic polyps, adenomas, and
serrated adenomas (30), and several experimental studies in-
dicate an IL-4 protumorigenic effect on CRC (31–33).
These results describe for the first time the adaptive Th17-
associated cytokine upregulation in serum of patients with mul-
tiple colonic polyps. Although further studies on in vitro Th
differentiation are needed, implications in immunomodulatory
strategiesmay be experimentally considered from this start point.
Whether biological therapies targeting IL-23 and related immune
checkpoints may be worth testing in preclinical models.
However, several environmental factors that could lead to
a proinflammatory state have been associated with colorectal ad-
enoma or cancer. In patients with type 2 diabetes, epidemiological
studies show an increased risk of CRC (34). Research suggests that
cigarette smoking promotes the development of polyps in the co-
lon, especially serrated polyps (35). In an analysis of 42 studies,
researchers found that current smokers were twice as likely as
nonsmokers to develop colon polyps (36). Obesity is also an
established risk factor for colorectal neoplasia and has been pos-
tulated to promote cancer development through inflammation-
related mechanisms (37,38). Studies show that patients with DM
(39) and smokers (40,41) have high CRP levels, and these factors
may contribute jointly to the increased risk of adenoma.Moreover,
Table 3. Linear regression analysis of inflammatory markers (IL-2, IL-4, IL-6, IL-17A, IL-23, and CRP) and their association with the
case–control group adjusted by sex, smoking, and presence of diabetes mellitus
Variables in multivariate analysis P-value Coefficient b 95% Confidence interval
IL-17A Attenuated polyposis ,0.001 1.213 0.693 to 1.733
Sex 0.616 0.168 20.494 to 0.830
Smoking 0.400 20.214 20.715 to 0.288
Diabetes mellitus 0.471 0.315 20.548 to 1.179
IL-23 Attenuated polyposis 0.001 3.666 1.569 to 5.764
Sex 0.850 0.254 22.410 to 2.919
Smoking 0.066 21.916 23.957 to 0.125
Diabetes mellitus 0.517 1.167 22.393 to 4.727
IL-2 Attenuated polyposis ,0.001 2.529 1.242 to 3.815
Sex 0.418 0.668 20.960 to 2.295
Smoking 0.969 0.025 21.224 to 1.273
Diabetes mellitus 0.511 0.723 21.446 to 2.892
IL-4 Attenuated polyposis ,0.001 4.254 2.260 to 6.249
Sex 0.141 1.887 20.636 to 4.411
Smoking 0.493 0.673 21.262 to 2.608
Diabetes mellitus 0.992 0.017 23.346 to 3.380
IL-6 Attenuated polyposis ,0.001 3.542 1.877 to 5.208
Sex 0.760 20.333 22.481 to 1.816
Smoking 0.236 0.970 20.642 to 2.582
Diabetes mellitus 0.532 0.888 21.917 to 3.694
CRP Attenuated polyposis 0.003 4.042 1.358 to 6.725
Sex 0.803 20.429 23.838 to 3.979
Smoking 0.268 21.468 24.079 to 1.144
Diabetes mellitus 0.489 1.597 22.957 to 6.151
CRP, C-reactive protein; IL, interleukin.
Figure 1. Differences in the serum concentrations of the Th17 pathway
interleukins between cases and controls: IL-17A (1.6 pg/mL vs 0.3 pg/mL),
IL-23 (22.1 pg/mL vs 17.7 pg/mL), and IL-6 (3.5 pg/mL vs 0.5 pg/mL).
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recent data also suggest that most of these environmental risk
factors are shared by both adenomas and serrated polyps (35). In
our study,we found that the increase in proinflammatory cytokines
is independentof thehighestproportionofDMand smokers found
in our cohort. This finding does not rule out a causal relationship
between these environmental factors and the increase of in-
flammatory cytokines, but it suggests that the highest frequency of
these environmental factors is not the only explanation for these
findings. Our results highlight the need for more research to un-
derstand the cross talk between environmental factors, in-
flammation, and development of colonic polyps and CRC. We
have also to remark the high proportion of men found in our cases
with multiple colonic polyps who could be related to the highest
prevalence ofCRC and colonic polyps inmen, but it is also possible
that men could be more affected by this cytokine dysregulation
found in our study.
Our study has some limitations. It is important to state the
heterogeneity of multiple colonic polyps in our study, with
patients with both adenomatous and serrated polyps in-
distinctly included. This study was unable to define whether
there are phenotypical differences in interleukin activation. In
addition, we have not made any longitudinal analysis in our
patients aimed to support ongoing stimuli of cytokine activation
in the genesis of attenuated polyposis phenotype. However, our
results are plausible and robust, with cases that were pro-
spectively recruited and controls with confirmed normal colo-
noscopy. Moreover, we cannot rule out the potential role of
unknown genetic factors in the genesis of this phenotype, with
potential germline mutations not yet found or potential genetic
predisposition to producing T cells that elaborate different
patterns of cytokines.
In summary, aside from the known genetic role of approxi-
mately 20%–30% of cases of attenuated polyposis, environmental
factors may play a role in this phenotype, leading to immuno-
logical responses and bowel inflammation. An increased Th17-
related immune response associated with smoking, DM, or
metabolic syndrome could jointly contribute to the increased risk
for the development of multiple colonic polyps. New studies
should be developed that aim to validate these results in different
cohorts and more clearly define the role of inflammation and the
effect of modulation of the immune response on the development
of this phenotype.
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Table 4. Polyp characteristics
Polyp characteristics
Mean no. of polyps 23
Polyp number, mean 6 SD
Proximal colon 7.7 6 8.2
Distal colon 11.7 6 10.5
Location, %
Proximal colon 40
Distal colon 60%
Adenomatous polyps
Predominant type of polyps, % (n) 55% (46)
Mean no. of adenomatous polyps 9
Adenomatous polyps, %
Rectosigmoid 29.6
Proximal to rectosigmoid 70.4
Patients with .10 adenomas, % (n) 30.1% (25)
Serrated polyps
Predominant type of polyps, % (n) 45% (37)
Mean no. of serrated polyps 9
Serrated polyps, %
Rectosigmoid 50.5
Proximal to rectosigmoid 49.5
Serrated polyposis syndrome 21.6% (8)
Table 5. Association between polyposis type (adenomatous or
serrated) and cytokine concentrations (IL-2, IL-4, IL-6, IL-17A,
IL-23, IL-11, IL-10, TNF-a, IFN-g, and CRP)
Polyposis type Adenomatous Serrated P
IL-17A 1.5 6 1.5 1.56 0.9 0.879
IL-23 6.16 4.6 7.36 6.1 0.466
IL-6 3.46 4.6 4 6 6.7 0.741
IL-11 8.86 16 6.5 6 11.1 0.502
IL-10 3.86 4.4 6 6 10 0.409
IL-2 2.26 3.2 4 6 5.8 0.237
IL-4 3.76 5.4 6.26 9.1 0.299
TNF-a 0.56 1.3 2.36 4.5 0.010a
IFN-g 1.36 3.7 1.36 3.7 0.954
CRP 4.3 6 8 5.16 9.6 0.768
All cytokine and inflammatory marker levels are presented as mean 6 SD.
CRP, C-reactive protein; IFN, interferon; IL, interleukin; TNF, tumor necrosis
factor.
aResults are statistically significant.
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fecal immunochemical test–based colorectal cancer
screening programs. In most cases, there are no genetic
causes for this phenotype, and these cases are of unknown
origin.
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smoking, can activate proinflammatory cytokines, resulting in
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WHAT IS NEW HERE
3 Proinflammatory Th17-related cytokines are significantly
increased in serum of patients with multiple colonic polyps of
unknown origin.
3 Our findings can be hypothesis generating for future studies
that aim to link the differentiation of this proinflammatory
adaptive immune response to the development of multiple
colonic polyps and open the possibility of investigating the
potential immunomodulatory treatments for this condition.
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